Mats Wahlstrom - Jan 7, 2022 Form 4/A - Amendment Insider Report for Coherus BioSciences, Inc. (CHRS)

Role
Director
Signature
/s/ McDavid Stilwell, as Attorney-in-Fact for Mats Wahlstrom
Stock symbol
CHRS
Transactions as of
Jan 7, 2022
Transactions value $
$0
Form type
4/A - Amendment
Date filed
2/11/2022, 03:11 PM
Date Of Original Report
Jan 10, 2022
Next filing
Mar 1, 2022

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction CHRS Stock Option (Right to Buy) Award $0 +27K $0.00 27K Jan 7, 2022 Common Stock 27K $14.67 Direct F1, F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The Form 4/A is being filed solely to correct a typographical error in the exercise price. Except as noted in this footnote, all other information as disclosed in the Reporting Person's original Form 4 was accurately reported.
F2 The underlying shares subject to the option vest and become exercisable as to 1/12th of the total number of shares subject to the option in successive, equal monthly installments measured from January 1, 2022, subject to Reporting Person's continued service relationship with the Issuer on each such vesting date.